Skip to main content
Natco Pharma Ltd. logo

Natco Pharma Ltd. — Investor Relations & Filings

Ticker · NATCOPHARM ISIN · INE987B01026 LEI · 33580086GIBRWXSNGG39 BSE.NS Manufacturing
Open in API
Filings indexed 1,708 across all filing types
Latest filing 2021-05-21 Regulatory Filings
Country IN India
Listing BSE.NS NATCOPHARM

About Natco Pharma Ltd.

https://www.natcopharma.co.in/

Natco Pharma Ltd. is a vertically integrated organization focused on the development, manufacturing, and marketing of complex generics and active pharmaceutical ingredients (APIs). The company specializes in niche therapeutic areas, maintaining a leadership position in oncology and a significant presence in specialty segments such as hepatology, cardiology, and diabetology. Natco is recognized for its expertise in high-barrier-to-entry products, including complex oral solids and injectables. Its business model emphasizes research and development to deliver affordable versions of life-saving medicines globally. With a robust portfolio of finished dosage formulations and a strong supply chain for APIs, the company serves diverse international markets, including North America, Europe, and emerging economies, through strategic partnerships and direct distribution channels.

Recent filings

Filing Released Lang Actions
NATCO starts Phase-III Clinical Trial of Molnupiravir capsules for Covid-19 treatment
Regulatory Filings
2021-05-21 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release announcing the initiation of a Phase-III clinical trial for Molnupiravir capsules by Natco Pharma Limited. It is addressed to stock exchanges and is intended for public information. The content focuses on a clinical trial update rather than financial results, management changes, or regulatory filings. It is not a financial report, earnings release, or regulatory filing. The document is a corporate announcement related to a clinical trial, which does not fit into the specific financial or corporate filing categories provided. Therefore, the best fit is Regulatory Filings (RNS), which serves as a fallback category for miscellaneous corporate announcements that do not fit other categories. The document length is short and it is a standalone announcement, not a report or presentation.
2021-05-21 English
Annual Secretarial Compliance Report for the year ended March 31, 2021
Regulatory Filings
2021-05-20 English
Press Release
Regulatory Filings Classification · 90% confidence The document text contains only placeholders for images and no substantive text content. The true document length is only 192 characters, which is extremely short and contains no financial data, report content, or announcements. It does not contain any report, announcement, or regulatory filing information. Given the lack of content, the best classification is Regulatory Filings (RNS) as a fallback category for miscellaneous filings that do not fit other categories.
2021-05-17 English
NATCO signs Voluntary Licensing Agreement with Lilly for Baricitinib for Covid-19 in India
Regulatory Filings
2021-05-17 English
NATCO receives Emergency Use approval for Baricitinib tablets for Covid-19 treatment
Regulatory Filings
2021-05-03 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.